03300: Probiotic Prevention of GI Hyperpermeability and Metabolome Disturbances in Dogs with Multicentric Lymphoma Undergoing Multi-drug Chemotherapy
Gastrointestinal (GI) side effects negatively impact dogs with lymphoma who are undergoing treatment with multi-drug chemotherapy. Up to 40% of dogs experience GI toxicity that requires dose reduction or treatment delays, which can increase the cost of care if hospitalization is required. As routinely prescribed medications inconsistently prevent GI toxicity, new options are needed. Disruption […]
03007: Chimeric BiTE-redirected Anti-viral T Cells for Fratricide of Minimal Residual Disease in T-cell Malignancies
T cells are front-line soldiers deployed throughout the body to defend against infections and cancer. Sometimes, a rogue T cell itself can become cancerous. These resulting blood cancers (lymphoma or leukemia) are unusually resistant to traditional chemotherapy drugs. Immunotherapy has revolutionized the treatment of chemo-resistant B-cell blood cancers, but targeting T cells must be far […]
02772: Identifying Early Stage Ultra-rare Mutations as Predictive Biomarkers of Lymphoma in High-risk versus Low-risk Breeds Within the Dog Aging Project
The most common type of cancer in dogs is lymphoma, with ~80,000 cases diagnosed annually in the United States. Breeds vary in their risk of lymphoma, but it is unclear why there is variation despite considerable effort to identify the genetics of cancer risk and progression in dogs. Cancer typically arises from the accumulation of […]
02309-T: Targeting the Cancer Epigenome: The Effect of Specific Histone Lysine Methyltransferase Inhibition in Canine B-Cell Lymphoma
Canine lymphoma is one of the most common cancers in dogs. While some breeds appear more at risk than others, all can be affected. While often treatable, canine lymphoma can rarely be cured. A continued understanding of the mechanisms causing lymphoma in dogs and identification of novel therapies are needed to improve survival in dogs […]
02316: Genetic Risk Factors for Canine T zone Lymphoma
The Golden Retriever is a breed that develops a variety of cancers at a high frequency. One type of cancer, T zone lymphoma, is so common in this breed that 40% of all cases are seen in Golden Retrievers. This observation suggests a clear genetic predisposition. The investigators have completed an environmental risk factor study […]
02885: Exposure to Environmental Chemicals in Boxers with Lymphoma
Lymphoma is a common and deadly cancer in dogs, and Boxers are one of several high-risk breeds. While breed-related risk for canine lymphoma is likely inherited, there is also epidemiologic evidence for environmental and potentially modifiable risk. Lymphoma correlates with areas of higher industrial activity in both humans and dogs, but the specific chemicals putting […]
02304-A: Investigating a Biomarker and Novel Therapeutic Target for Canine Diffuse Large B Cell Lymphoma
Canine diffuse large B-cell lymphoma (DLBCL) is a common, aggressive cancer in dogs. The average survival time after initial diagnosis is one year. Unfortunately, the diagnosis of DLBCL is often made late in disease when the cancer is advanced, which negatively impacts the survival of the dog. Therefore, there is a need to 1) develop […]
02315-A: Discovering Peptide Targets for Development of Adoptive Cell Therapy for Peripheral T-Cell Lymphoma
T cells (a type of white blood cell known as a lymphocyte) constitute the immune system’s most potent weapons against cancer, but growing malignant cells can quickly outpace and overwhelm these defenses. In the most advanced form of cancer immunotherapy, these T cells can be isolated from the body, reinvigorated and expanded to vast numbers […]
02317: The Role of Complex Translocations Associated with TP53 Somatic Mutations for Aiding Prognosis of Canine Diffuse Large B cell Lymphoma
Lymphoma accounts for up to 24% of all cancers diagnosed in pet dogs. Among these cases diffuse large B-cell lymphoma (DLBCL) is the most common subtype. Despite continued advances in veterinary medicine, the response to treatment for canine lymphoma remains highly variable with no reliable means to predict response. Studies of lymphoma in people have […]
02092-A: Developing the Use of a Novel Imaging Technique to Define a Dog’s Potential Responsiveness to Chemotherapy
Lymphoma is one of the most common cancers in pet dogs. Although this cancer responds well to chemotherapy, the duration of cancer remission and survival time afforded by chemotherapy differ dramatically from dog to dog, with some dogs’ cancers responding less favorably to chemotherapy than others. Unfortunately, there are no current tests that can predict […]